C-Myc Expression in Oral Squamous Cell Carcinoma: Molecular Mechanisms in Cell Survival and Cancer Progression.
Cal-27
c-Myc
doxorubicin
squamous cell carcinoma
tumor microenvironment
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
19 Jul 2022
19 Jul 2022
Historique:
received:
19
05
2022
revised:
15
07
2022
accepted:
16
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Oral squamous cell carcinoma (OSCC) represents 90% of malignant epithelial cancer that occurs in the oral cavity. The c-Myc factor is expressed in multiple types of cancer, comprising head and neck squamous cell carcinoma (HNSCC), where it plays a fundamental role in tumor prognosis and in the self-renewal of tumor stem cells. However, the role of c-Myc in controlling OSCC cells is not well-known. The aim of the present study is the evaluation of the biological roles and regulatory mechanism of c-Myc in the pathogenesis of OSCC. Results indicated that c-Myc, c-Jun, Bcl-2, hypoxia inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), ERK 1/2 and pERK1/2 were overexpressed in a cellular model of squamous cell carcinoma, Cal-27. Doxorubicin (Doxo), a common chemotherapeutic agent, inhibited cell invasion, hypoxia, angiogenesis and inflammation in a cellular model of Cal-27 cells as indicated by downregulation of MMP-9, VEGF, ERK 1/2 and pERK 1/2 as well as promoted apoptosis as evidenced by the downregulation of Bcl-2 protein. This work aimed at underlying the functional relevance of c-Myc in OSCC and the HIF-Myc collaboration by integrating the knowledge on this molecular link in an OSCC tumor microenvironment. The results obtained showed for the first time the vital role of c-Myc in Cal-27 in cell survival/proliferation and tumor growth as well as the negative regulatory effect of Doxo against c-Myc signaling pathway.
Identifiants
pubmed: 35890188
pii: ph15070890
doi: 10.3390/ph15070890
pmc: PMC9316231
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cell Death Dis. 2022 Apr 12;13(4):338
pubmed: 35414060
Int J Biol Macromol. 2020 May 1;150:1000-1010
pubmed: 31751739
Oxid Med Cell Longev. 2021 Jan 19;2021:6679708
pubmed: 33542783
Annu Rev Genet. 1986;20:361-84
pubmed: 3028245
Front Cell Dev Biol. 2020 Nov 05;8:590576
pubmed: 33251216
Clin Cancer Res. 2017 Jun 15;23(12):3120-3128
pubmed: 27965308
Curr Top Dev Biol. 2006;76:217-57
pubmed: 17118268
J Cell Biochem. 2011 Sep;112(9):2508-17
pubmed: 21557297
Adv Hematol. 2012;2012:524308
pubmed: 21941553
Front Oncol. 2020 Nov 26;10:581208
pubmed: 33324557
Oncogene. 1989 Dec;4(12):1463-8
pubmed: 2687767
Oral Oncol. 2018 May;80:23-32
pubmed: 29706185
Cancer Invest. 2016 Sep 13;34(8):393-400
pubmed: 27558649
Sci Rep. 2021 Jan 18;11(1):1725
pubmed: 33462277
Asian Pac J Cancer Prev. 2013;14(5):2689-98
pubmed: 23803016
J Biomed Biotechnol. 2011;2011:567305
pubmed: 22007144
Cancer Manag Res. 2019 Jun 05;11:5163-5169
pubmed: 31239771
Cancer Biol Ther. 2022 Dec 31;23(1):34-50
pubmed: 34978469
Int J Mol Cell Med. 2021 Winter;10(1):45-55
pubmed: 34268253
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Biomed Pharmacother. 2020 May;125:109962
pubmed: 32106373
Int J Oncol. 2009 Apr;34(4):897-903
pubmed: 19287946
Curr Opin Otolaryngol Head Neck Surg. 2012 Apr;20(2):142-7
pubmed: 22249168
Acta Pharm Sin B. 2015 Sep;5(5):378-89
pubmed: 26579469
Eur J Cancer. 2005 Nov;41(16):2449-61
pubmed: 16199154
J Mater Chem B. 2021 Aug 4;9(30):6006-6016
pubmed: 34282440
Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14152-7
pubmed: 20660764
Sci Rep. 2017 Oct 31;7(1):14419
pubmed: 29089545
Cell Cycle. 2010 May;9(9):1722-8
pubmed: 20404562
Cancer Sci. 2022 Jan;113(1):319-333
pubmed: 34714590
J Oral Maxillofac Pathol. 2018 Sep-Dec;22(3):325-331
pubmed: 30651675
Oncol Lett. 2019 Jan;17(1):1257-1266
pubmed: 30655893
Cancers (Basel). 2020 Jul 31;12(8):
pubmed: 32751922
Cancers (Basel). 2021 Jun 17;13(12):
pubmed: 34204259
Biomed Res Int. 2015;2015:549412
pubmed: 26146622
Antioxidants (Basel). 2022 Feb 15;11(2):
pubmed: 35204269
Crit Rev Oncog. 1993;4(4):435-49
pubmed: 8353142
J Pathol. 2014 Oct;234(2):190-202
pubmed: 24852265